hypericin has been researched along with Glial Cell Tumors in 26 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Hypericin is a potent inhibitor of glioma growth in vitro." | 9.15 | A phase 1/2 study of orally administered synthetic hypericin for treatment of recurrent malignant gliomas. ( Appley, AJ; Cabana, BE; Chen, TC; Couldwell, WT; Forsyth, PA; Hinton, DR; Spence, AM; Stillerman, CB; Surnock, AA; Tobia, AJ, 2011) |
| "The viability of U87 MG glioma cells in the presence of rottlerin and hypericin was assessed by MTT assay and flow cytometry in the absence and presence of light." | 7.85 | Synergism between PKCδ regulators hypericin and rottlerin enhances apoptosis in U87 MG glioma cells after light stimulation. ( Horvath, D; Huntosova, V; Miskovsky, P; Misuth, M, 2017) |
| " We show the localization of Bax and Bak in U-87 MG human glioma cells incubated with photosensitizer hypericin (Hyp) before and after photodynamic action." | 7.79 | Bcl-2 proapoptotic proteins distribution in U-87 MG glioma cells before and after hypericin photodynamic action. ( Balogová, L; Dzurová, L; Maslaňáková, M; Miškovský, P; Stroffeková, K, 2013) |
| "In a syngeneic subcutaneous glioma mouse model we investigated the time dependent hypericin (HYP) uptake in malignant tumor tissue by microendoscopically fluorescence measurements." | 7.79 | Microendoscopy for hypericin fluorescence tumor diagnosis in a subcutaneous glioma mouse model. ( Ehrhardt, A; Feigl, GC; Göbel, W; Mayer, D; Naumann, U; Noell, S; Ritz, R; Serifi, D, 2013) |
| "In five patients with a recurrence of a malignant glioma a newly developed water soluble formulation of hypericin was given intravenously (0." | 7.78 | Hypericin for visualization of high grade gliomas: first clinical experience. ( Bornemann, A; Daniels, R; Dietz, K; Feigl, GC; Mayer, D; Noell, S; Ramina, K; Ritz, R; Schmidt, V; Strauss, WS; Tatagiba, M, 2012) |
| " Hypericin (HY) exhibit high phototoxicity to malignant cells and accumulates to a higher extent in glioblastoma cells as compared to neurons." | 7.74 | Photodynamic therapy of malignant glioma with hypericin: comprehensive in vitro study in human glioblastoma cell lines. ( Dietz, K; Ritz, R; Roser, F; Schenk, M; Strauss, WS; Tatagiba, M; Wein, HT, 2007) |
| " We studied the interrelation of proliferation and migration in the presence of different protein-kinase-C(PKC) inhibitors (TAM, staurosporine, hypericin) in 2 glioma cell lines." | 7.70 | Tamoxifen-resistant glioma-cell sub-populations are characterized by increased migration and proliferation. ( Giese, A; Puchner, MJ, 2000) |
| "Hypericin and tamoxifen are experimental agents for the adjuvant chemotherapy of malignant glioma." | 7.69 | Hypericin-induced apoptosis of human malignant glioma cells is light-dependent, independent of bcl-2 expression, and does not require wild-type p53. ( Bremen, D; Grimmel, C; Krajewski, S; Reed, JC; Schabet, M; Trepel, M; Weller, M, 1997) |
| "The effect of hypericin, an antiviral drug and a potent protein kinase C (PKC) inhibitor, on glioma cell invasion was investigated in vitro." | 7.69 | Inhibition of human malignant glioma cell motility and invasion in vitro by hypericin, a potent protein kinase C inhibitor. ( Couldwell, WT; Hinton, DR; Law, RE; Zhang, W, 1997) |
| "Hypericin (Hyp) is a hydrophobic natural photosensitizer that is considered to be a promising molecule for photodynamic treatment of tumor cells and photo-diagnosis of early epithelial cancers." | 5.38 | Cell death response of U87 glioma cells on hypericin photoactivation is mediated by dynamics of hypericin subcellular distribution and its aggregation in cellular organelles. ( Dzurova, L; Huntosova, V; Jakusova, V; Miskovsky, P; Nadova, Z; Sureau, F, 2012) |
| "Malignant gliomas are diffuse infiltrative growing tumors with a poor prognosis despite treatment with a combination of surgery, radiotherapy and chemotherapy." | 5.37 | Selective enrichment of hypericin in malignant glioma: pioneering in vivo results. ( Mayer, D; Noell, S; Ritz, R; Strauss, WS; Tatagiba, MS, 2011) |
| "Three patients suffered from an anaplastic astrocytoma, WHO grade III, nine had a glioblastoma, WHO grade IV." | 5.35 | Hypericin uptake: a prognostic marker for survival in high-grade glioma. ( Bornemann, A; Dietz, K; Duffner, F; Müller, M; Ritz, R; Roser, F; Tatagiba, M, 2008) |
| "Hypericin is a potent inhibitor of glioma growth in vitro." | 5.15 | A phase 1/2 study of orally administered synthetic hypericin for treatment of recurrent malignant gliomas. ( Appley, AJ; Cabana, BE; Chen, TC; Couldwell, WT; Forsyth, PA; Hinton, DR; Spence, AM; Stillerman, CB; Surnock, AA; Tobia, AJ, 2011) |
| "The viability of U87 MG glioma cells in the presence of rottlerin and hypericin was assessed by MTT assay and flow cytometry in the absence and presence of light." | 3.85 | Synergism between PKCδ regulators hypericin and rottlerin enhances apoptosis in U87 MG glioma cells after light stimulation. ( Horvath, D; Huntosova, V; Miskovsky, P; Misuth, M, 2017) |
| " We show the localization of Bax and Bak in U-87 MG human glioma cells incubated with photosensitizer hypericin (Hyp) before and after photodynamic action." | 3.79 | Bcl-2 proapoptotic proteins distribution in U-87 MG glioma cells before and after hypericin photodynamic action. ( Balogová, L; Dzurová, L; Maslaňáková, M; Miškovský, P; Stroffeková, K, 2013) |
| "In a syngeneic subcutaneous glioma mouse model we investigated the time dependent hypericin (HYP) uptake in malignant tumor tissue by microendoscopically fluorescence measurements." | 3.79 | Microendoscopy for hypericin fluorescence tumor diagnosis in a subcutaneous glioma mouse model. ( Ehrhardt, A; Feigl, GC; Göbel, W; Mayer, D; Naumann, U; Noell, S; Ritz, R; Serifi, D, 2013) |
| "In five patients with a recurrence of a malignant glioma a newly developed water soluble formulation of hypericin was given intravenously (0." | 3.78 | Hypericin for visualization of high grade gliomas: first clinical experience. ( Bornemann, A; Daniels, R; Dietz, K; Feigl, GC; Mayer, D; Noell, S; Ramina, K; Ritz, R; Schmidt, V; Strauss, WS; Tatagiba, M, 2012) |
| " Hypericin (HY) exhibit high phototoxicity to malignant cells and accumulates to a higher extent in glioblastoma cells as compared to neurons." | 3.74 | Photodynamic therapy of malignant glioma with hypericin: comprehensive in vitro study in human glioblastoma cell lines. ( Dietz, K; Ritz, R; Roser, F; Schenk, M; Strauss, WS; Tatagiba, M; Wein, HT, 2007) |
| " We studied the interrelation of proliferation and migration in the presence of different protein-kinase-C(PKC) inhibitors (TAM, staurosporine, hypericin) in 2 glioma cell lines." | 3.70 | Tamoxifen-resistant glioma-cell sub-populations are characterized by increased migration and proliferation. ( Giese, A; Puchner, MJ, 2000) |
| "Hypericin and tamoxifen are experimental agents for the adjuvant chemotherapy of malignant glioma." | 3.69 | Hypericin-induced apoptosis of human malignant glioma cells is light-dependent, independent of bcl-2 expression, and does not require wild-type p53. ( Bremen, D; Grimmel, C; Krajewski, S; Reed, JC; Schabet, M; Trepel, M; Weller, M, 1997) |
| "The effect of hypericin, an antiviral drug and a potent protein kinase C (PKC) inhibitor, on glioma cell invasion was investigated in vitro." | 3.69 | Inhibition of human malignant glioma cell motility and invasion in vitro by hypericin, a potent protein kinase C inhibitor. ( Couldwell, WT; Hinton, DR; Law, RE; Zhang, W, 1997) |
| "Hypericin (Hyp) is a naturally occurring compound used as photosensitizer in photodynamic therapy and diagnosis." | 1.51 | Importance of Hypericin-Bcl2 interactions for biological effects at subcellular levels. ( Huntosova, V; Kozar, T; Stroffekova, K; Tomkova, S, 2019) |
| "Hypericin (Hyp) is a hydrophobic natural photosensitizer that is considered to be a promising molecule for photodynamic treatment of tumor cells and photo-diagnosis of early epithelial cancers." | 1.38 | Cell death response of U87 glioma cells on hypericin photoactivation is mediated by dynamics of hypericin subcellular distribution and its aggregation in cellular organelles. ( Dzurova, L; Huntosova, V; Jakusova, V; Miskovsky, P; Nadova, Z; Sureau, F, 2012) |
| "Malignant gliomas are diffuse infiltrative growing tumors with a poor prognosis despite treatment with a combination of surgery, radiotherapy and chemotherapy." | 1.37 | Selective enrichment of hypericin in malignant glioma: pioneering in vivo results. ( Mayer, D; Noell, S; Ritz, R; Strauss, WS; Tatagiba, MS, 2011) |
| "Three patients suffered from an anaplastic astrocytoma, WHO grade III, nine had a glioblastoma, WHO grade IV." | 1.35 | Hypericin uptake: a prognostic marker for survival in high-grade glioma. ( Bornemann, A; Dietz, K; Duffner, F; Müller, M; Ritz, R; Roser, F; Tatagiba, M, 2008) |
| "Hypericin treatment (6." | 1.33 | Hypericin-an inhibitor of proteasome function. ( Fiebich, B; Pajonk, F; Scholber, J, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (19.23) | 18.2507 |
| 2000's | 5 (19.23) | 29.6817 |
| 2010's | 15 (57.69) | 24.3611 |
| 2020's | 1 (3.85) | 2.80 |
| Authors | Studies |
|---|---|
| Bassler, MC | 1 |
| Rammler, T | 1 |
| Wackenhut, F | 1 |
| Zur Oven-Krockhaus, S | 1 |
| Secic, I | 1 |
| Ritz, R | 6 |
| Meixner, AJ | 1 |
| Brecht, M | 1 |
| Stroffekova, K | 5 |
| Tomkova, S | 1 |
| Huntosova, V | 9 |
| Kozar, T | 2 |
| Misuth, M | 3 |
| Horvath, D | 4 |
| Miskovsky, P | 7 |
| Balogová, L | 2 |
| Maslaňáková, M | 2 |
| Dzurová, L | 4 |
| Noell, S | 3 |
| Feigl, GC | 2 |
| Serifi, D | 1 |
| Mayer, D | 3 |
| Naumann, U | 1 |
| Göbel, W | 1 |
| Ehrhardt, A | 1 |
| Petrovajova, D | 2 |
| Nadova, Z | 3 |
| Garg, AD | 1 |
| Vandenberk, L | 1 |
| Koks, C | 1 |
| Verschuere, T | 1 |
| Boon, L | 1 |
| Van Gool, SW | 1 |
| Agostinis, P | 1 |
| Verebova, V | 1 |
| Belej, D | 2 |
| Joniova, J | 3 |
| Jurasekova, Z | 1 |
| Stanicova, J | 1 |
| Hrivnak, S | 1 |
| Novotova, M | 2 |
| Nichtova, Z | 2 |
| Shibata, Y | 1 |
| Alvarez, L | 1 |
| Bryndzova, L | 1 |
| Jancura, D | 1 |
| Buriankova, L | 1 |
| Bonneau, S | 1 |
| Brault, D | 1 |
| Sureau, F | 3 |
| Strauss, WS | 3 |
| Tatagiba, MS | 1 |
| Couldwell, WT | 4 |
| Surnock, AA | 1 |
| Tobia, AJ | 1 |
| Cabana, BE | 1 |
| Stillerman, CB | 1 |
| Forsyth, PA | 1 |
| Appley, AJ | 1 |
| Spence, AM | 1 |
| Hinton, DR | 4 |
| Chen, TC | 1 |
| Daniels, R | 1 |
| Schmidt, V | 1 |
| Bornemann, A | 2 |
| Ramina, K | 1 |
| Dietz, K | 3 |
| Tatagiba, M | 3 |
| Jakusova, V | 1 |
| Pajonk, F | 1 |
| Scholber, J | 1 |
| Fiebich, B | 1 |
| Wein, HT | 1 |
| Schenk, M | 1 |
| Roser, F | 2 |
| Müller, M | 1 |
| Duffner, F | 1 |
| Gopalakrishna, R | 2 |
| He, S | 1 |
| Weiss, MH | 2 |
| Law, RE | 4 |
| Apuzzo, ML | 1 |
| Weller, M | 1 |
| Trepel, M | 1 |
| Grimmel, C | 1 |
| Schabet, M | 1 |
| Bremen, D | 1 |
| Krajewski, S | 1 |
| Reed, JC | 1 |
| Zhang, W | 2 |
| Anker, L | 1 |
| Pu, Q | 1 |
| Gundimeda, U | 1 |
| Miccoli, L | 1 |
| Beurdeley-Thomas, A | 1 |
| De Pinieux, G | 1 |
| Oudard, S | 1 |
| Dutrillaux, B | 1 |
| Poupon, MF | 1 |
| Puchner, MJ | 1 |
| Giese, A | 1 |
1 trial available for hypericin and Glial Cell Tumors
| Article | Year |
|---|---|
A phase 1/2 study of orally administered synthetic hypericin for treatment of recurrent malignant gliomas.
Topics: Administration, Oral; Adolescent; Adult; Aged; Anthracenes; Antineoplastic Agents; Brain Neoplasms; | 2011 |
25 other studies available for hypericin and Glial Cell Tumors
| Article | Year |
|---|---|
Accumulation and penetration behavior of hypericin in glioma tumor spheroids studied by fluorescence microscopy and confocal fluorescence lifetime imaging microscopy.
Topics: Anthracenes; Brain Neoplasms; Cell Line, Tumor; Glioma; Humans; Microscopy, Fluorescence; Perylene; | 2022 |
Importance of Hypericin-Bcl2 interactions for biological effects at subcellular levels.
Topics: Aniline Compounds; Anthracenes; Cell Line, Tumor; Cell Survival; Fluorescence; Glioma; Humans; Molec | 2019 |
Synergism between PKCδ regulators hypericin and rottlerin enhances apoptosis in U87 MG glioma cells after light stimulation.
Topics: Acetophenones; Angiogenesis Inhibitors; Anthracenes; Antineoplastic Agents; Apoptosis; Benzopyrans; | 2017 |
Bcl-2 proapoptotic proteins distribution in U-87 MG glioma cells before and after hypericin photodynamic action.
Topics: Anthracenes; Apoptosis; Cell Line, Tumor; Glioma; Humans; Light; Perylene; Photochemotherapy; Photos | 2013 |
Microendoscopy for hypericin fluorescence tumor diagnosis in a subcutaneous glioma mouse model.
Topics: Animals; Anthracenes; Brain Neoplasms; Cell Line, Tumor; Disease Models, Animal; Endoscopy; Glioma; | 2013 |
The role of anti-apoptotic protein kinase Cα in response to hypericin photodynamic therapy in U-87 MG cells.
Topics: Anthracenes; Apoptosis Regulatory Proteins; Cell Line, Tumor; Glioma; Humans; Perylene; Phosphorylat | 2014 |
Dendritic cell vaccines based on immunogenic cell death elicit danger signals and T cell-driven rejection of high-grade glioma.
Topics: Adaptive Immunity; Animals; Anthracenes; Apoptosis; Brain Neoplasms; Cancer Vaccines; CD8-Positive T | 2016 |
Deeper insights into the drug defense of glioma cells against hydrophobic molecules.
Topics: Anthracenes; Anthraquinones; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tum | 2016 |
Estimation of PKCδ autophosphorylation in U87 MG glioma cells: combination of experimental, conceptual and numerical approaches.
Topics: Anthracenes; Blotting, Western; Cell Line, Tumor; Cell Nucleus; Ceramides; Computer Simulation; Glio | 2017 |
Assessing light-independent effects of hypericin on cell viability, ultrastructure and metabolism in human glioma and endothelial cells.
Topics: Anthracenes; Apoptosis; Cell Line, Tumor; Cell Respiration; Endothelial Cells; Glioma; Glycolysis; H | 2017 |
The flashlights on a distinct role of protein kinase C δ: Phosphorylation of regulatory and catalytic domain upon oxidative stress in glioma cells.
Topics: Algorithms; Anthracenes; Apoptosis; Brain Neoplasms; Catalytic Domain; Cell Line, Tumor; Glioma; Hum | 2017 |
Comment on "Hypericin uptake: a prognostic marker for survival in high-grade glioma".
Topics: Anthracenes; Brain Neoplasms; Glioma; Humans; Perylene | 2009 |
Interaction dynamics of hypericin with low-density lipoproteins and U87-MG cells.
Topics: Anthracenes; Cell Line, Tumor; Cell Membrane; Fluorescence; Glioma; Humans; Hydrophobic and Hydrophi | 2010 |
Selective enrichment of hypericin in malignant glioma: pioneering in vivo results.
Topics: Animals; Anthracenes; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Glioma; Male; Neopla | 2011 |
Hypericin for visualization of high grade gliomas: first clinical experience.
Topics: Aged; Anthracenes; Brain Neoplasms; Female; Fluorescence; Glioma; Humans; Injections, Intravenous; M | 2012 |
Cell death response of U87 glioma cells on hypericin photoactivation is mediated by dynamics of hypericin subcellular distribution and its aggregation in cellular organelles.
Topics: Anthracenes; Apoptosis; Cell Line, Tumor; Endocytosis; Fluorescence Resonance Energy Transfer; Gliom | 2012 |
Hypericin-an inhibitor of proteasome function.
Topics: Anthracenes; Antidepressive Agents; Electrophoretic Mobility Shift Assay; Glioma; Humans; Mammary Ne | 2005 |
Photodynamic therapy of malignant glioma with hypericin: comprehensive in vitro study in human glioblastoma cell lines.
Topics: Anthracenes; Brain Neoplasms; Cell Line, Tumor; Cell Membrane; Glioblastoma; Glioma; Humans; Light; | 2007 |
Hypericin uptake: a prognostic marker for survival in high-grade glioma.
Topics: Adult; Aged; Anthracenes; Astrocytoma; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Diseas | 2008 |
Hypericin: a potential antiglioma therapy.
Topics: Anthracenes; Apoptosis; Brain Neoplasms; Cell Division; Cell Line; Cell Survival; DNA Damage; Dose-R | 1994 |
Hypericin-induced apoptosis of human malignant glioma cells is light-dependent, independent of bcl-2 expression, and does not require wild-type p53.
Topics: Anthracenes; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Ap | 1997 |
Inhibition of human malignant glioma cell motility and invasion in vitro by hypericin, a potent protein kinase C inhibitor.
Topics: Anthracenes; Antineoplastic Agents; Brain Neoplasms; Cell Movement; Cells, Cultured; Enzyme Inhibito | 1997 |
Enhancement of radiosensitivity in human malignant glioma cells by hypericin in vitro.
Topics: Anthracenes; Glioma; Humans; Perylene; Protein Kinase C; Radiation-Sensitizing Agents; Tumor Cells, | 1996 |
Light-induced photoactivation of hypericin affects the energy metabolism of human glioma cells by inhibiting hexokinase bound to mitochondria.
Topics: Anthracenes; Apoptosis; Energy Metabolism; Enzyme Inhibitors; Glioma; Hexokinase; Humans; Hydrogen-I | 1998 |
Tamoxifen-resistant glioma-cell sub-populations are characterized by increased migration and proliferation.
Topics: Anthracenes; Antineoplastic Agents, Hormonal; Cell Division; Cell Movement; Dose-Response Relationsh | 2000 |